<p>InflaRx (NASDAQ:IFRX - 获取免费报告) 将在 8 月 8 日星期四市场开盘前公布其财报。分析师预计公司将公布本季度每股亏损$0.21 的收益。</p>
<p>InflaRx (NASDAQ:IFRX - 获取免费报告) 上次公布财报是在 5 月 8 日星期三。公司报告本季度每股亏损$0.19，超过分析师预期的$0.05。本季度公司营收为$0.04 百万美元，低于分析师预期的$1.76 百万美元。平均而言，分析师预计 InflaRx 本财年每股亏损$-1，下一财年每股亏损$-1。</p>
<h2>InflaRx 价格表现</h2>
<p>周五，纳斯达克股票代码为 IFRX 的股票下跌$0.06，收于$1.46。公司交易量为 7,559 股，低于平均交易量 191,815 股。该公司市值为$85.96 百万美元，市盈率为-1.95，贝塔系数为 1.58。公司的 50 天简单移动平均线为$1.57，200 天简单移动平均线为$1.54。InflaRx 的 12 个月最低价为$1.14，最高价为$4.30。</p>
<h2>华尔街分析师观点</h2>
<p>另外，HC Wainwright 重申了对 InflaRx 的 “买入” 评级，并设定了 6 月 24 日星期一的$8.00 目标价。</p>
<p><strong>查看我们关于 IFRX 的最新股票报告</strong></p>
<h2>关于 InflaRx (获取免费报告)</h2>
<p>InflaRx N.V.是一家临床阶段的生物制药公司，利用 C5a 技术在德国和美国发现和开发抑制剂。该公司的 C5a 是一种参与多种自身免疫和其他炎症性疾病进展的炎症介质。其主要产品候选药物是 vilobelimab，一种新型静脉注射的首创抗 C5a 单克隆抗体，已完成用于治疗汗腺炎的第三期临床试验，这是一种罕见的慢性致残性全身性炎症性皮肤病；用于治疗抗中性粒细胞胞浆抗体相关血管炎，这是一种罕见且危及生命的自身免疫疾病，目前处于第二期试验阶段；用于治疗化脓性坏疽，一种慢性炎症性皮肤疾病，目前处于第二期 a 探索性研究阶段；以及用于治疗 PD-1/PD-L1 抑制剂耐药/难治的局部晚期或转移性鳞状细胞癌，目前处于第二期临床开发阶段。</p>
<h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票比 InflaRx 更好</li>
<li>如何投资小市值股票</li>
<li>亚马逊股票在 AI 泡沫破裂后有望强劲反弹</li>
<li>投资高市盈率成长股</li>
<li>壳牌股票：石油和天然气巨头致力于回购和股息</li>
<li>顶尖生物科技股票：探索创新机会</li>
<li>雪佛龙股价下跌，盈利不及预期突显合并不确定性</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA"/></p>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 的编辑团队审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 时间不多了-6 月 25 日截止！（来自 Paradigm Press）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEx"/></p>
<h2>现在是否值得投资$1,000 购买 InflaRx?</h2>
<p>在考虑 InflaRx 之前，您会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 InflaRx 不在名单上。</p>
<p>尽管 InflaRx 目前在分析师中有 “强烈买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

IFRX

<p>InflaRx（纳斯达克股票代码：IFRX）将于 8 月 8 日星期四发布其季度财报。分析师预计该季度每股盈利为（$0.21）。InflaRx 是一家临床阶段的生物制药公司，致力于开发用于炎症性疾病的抑制剂。其主力产品候选药物是 vilobelimab，一种新型抗 C5a 单克隆抗体。该公司上一次在五月份报告的每股盈利为（$0.19），超过了分析师的预期。InflaRx 的市值为 8,596 万美元</p>

<p>InflaRx (NASDAQ:IFRX - Get Free Report) will be announcing its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.</p>
<div class="lb-trans"><p>InflaRx (NASDAQ:IFRX - 获取免费报告) 将在 8 月 8 日星期四市场开盘前公布其财报。分析师预计公司将公布本季度每股亏损$0.21 的收益。</p>
</div><p>InflaRx (NASDAQ:IFRX - Get Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.05. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $1.76 million. On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>InflaRx (NASDAQ:IFRX - 获取免费报告) 上次公布财报是在 5 月 8 日星期三。公司报告本季度每股亏损$0.19，超过分析师预期的$0.05。本季度公司营收为$0.04 百万美元，低于分析师预期的$1.76 百万美元。平均而言，分析师预计 InflaRx 本财年每股亏损$-1，下一财年每股亏损$-1。</p>
</div><h2>InflaRx Price Performance</h2>
<div class="lb-trans"><h2>InflaRx 价格表现</h2>
</div><p>Shares of NASDAQ:IFRX traded down $0.06 during trading on Friday, reaching $1.46. 7,559 shares of the company were exchanged, compared to its average volume of 191,815. The firm has a market capitalization of $85.96 million, a PE ratio of -1.95 and a beta of 1.58. The business's fifty day simple moving average is $1.57 and its 200-day simple moving average is $1.54. InflaRx has a 12-month low of $1.14 and a 12-month high of $4.30.</p>
<div class="lb-trans"><p>周五，纳斯达克股票代码为 IFRX 的股票下跌$0.06，收于$1.46。公司交易量为 7,559 股，低于平均交易量 191,815 股。该公司市值为$85.96 百万美元，市盈率为-1.95，贝塔系数为 1.58。公司的 50 天简单移动平均线为$1.57，200 天简单移动平均线为$1.54。InflaRx 的 12 个月最低价为$1.14，最高价为$4.30。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Separately, HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $8.00 target price on shares of InflaRx in a research report on Monday, June 24th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 重申了对 InflaRx 的 “买入” 评级，并设定了 6 月 24 日星期一的$8.00 目标价。</p>
</div><p><strong>Check Out Our Latest Stock Report on IFRX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 IFRX 的最新股票报告</strong></p>
</div><h2>About InflaRx (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 InflaRx (获取免费报告)</h2>
</div><p>InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.</p>
<div class="lb-trans"><p>InflaRx N.V.是一家临床阶段的生物制药公司，利用 C5a 技术在德国和美国发现和开发抑制剂。该公司的 C5a 是一种参与多种自身免疫和其他炎症性疾病进展的炎症介质。其主要产品候选药物是 vilobelimab，一种新型静脉注射的首创抗 C5a 单克隆抗体，已完成用于治疗汗腺炎的第三期临床试验，这是一种罕见的慢性致残性全身性炎症性皮肤病；用于治疗抗中性粒细胞胞浆抗体相关血管炎，这是一种罕见且危及生命的自身免疫疾病，目前处于第二期试验阶段；用于治疗化脓性坏疽，一种慢性炎症性皮肤疾病，目前处于第二期 a 探索性研究阶段；以及用于治疗 PD-1/PD-L1 抑制剂耐药/难治的局部晚期或转移性鳞状细胞癌，目前处于第二期临床开发阶段。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than InflaRx</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Shell Stock: Oil &amp; Gas Giant Committed to Buybacks and Dividends</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Chevron Stock Dips as Earnings Miss Highlights Merger Uncertainty</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票比 InflaRx 更好</li>
<li>如何投资小市值股票</li>
<li>亚马逊股票在 AI 泡沫破裂后有望强劲反弹</li>
<li>投资高市盈率成长股</li>
<li>壳牌股票：石油和天然气巨头致力于回购和股息</li>
<li>顶尖生物科技股票：探索创新机会</li>
<li>雪佛龙股价下跌，盈利不及预期突显合并不确定性</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IFRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 的编辑团队审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 时间不多了-6 月 25 日截止！（来自 Paradigm Press）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9011&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in InflaRx right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 购买 InflaRx?</h2>
</div><p>Before you consider InflaRx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 InflaRx 之前，您会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 InflaRx 不在名单上。</p>
</div><p>While InflaRx currently has a &#34;Strong Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 InflaRx 目前在分析师中有 “强烈买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

InflaRx (IFRX) 将于周四公布季度财报